EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group

Ornnicha Sathitakorn iD, Sirorat Kobbuaklee, Chantiya Chanswangphuwana, Thanawat Rattanathammethee, Nisa Makruasi, Anothai Chintabanyat, Suporn Chuncharunee, Pisa Phiphitaporn, Archrob Khuhapinant, Peerapon Wong, Jakrawadee Julamanee, Chayapa Thookhamme und 5 weitere

Journal of Clinical Laboratory Analysis · 2025

DOI: 10.1002/jcla.70116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2025. Verfasst von Ornnicha Sathitakorn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Flow Cytometry, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ratchadapiseksompotch fund, Center of Excellence in Translational Hematology, Janssen Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Accurate diagnosis of chronic lymphocytic leukemia (CLL) is crucial for effective management. Although recent advancements in flow cytometry have significantly improved diagnostic accuracy, distinguishing atypical cases of CLL remains challenging. This study aimed to identify specific markers to enhance CLL diagnosis and prognostic assessment.

Methods

Blood or bone marrow from patients presenting with persistent lymphocytosis (> 5 × 10 3 /μL) was collected. Flow cytometric analysis was performed using a customized CLL panel to evaluate the expression of CD markers for the diagnosis of CLL. Clinical and laboratory data were reviewed to support the CLL diagnosis.

Results

A total of 228 patients were included in the study, including 206 patients (90.4%) in the CLL group and 22 patients (9.6%) in the non‐CLL group. The use of CD5, CD19, and CD200 in combination for diagnosing CLL demonstrated a sensitivity of 82.5% (95% CI, 76.6–87.4) and a specificity of 90.9% (95% CI, 70.8–98.9). In the final predictive model, which incorporated five markers (CD5, CD19, CD200, CD31, and CD11c), both specificity and positive predictive value for CLL diagnosis were close to 100% (95% CI, 84.6–100 and 95.5–100, respectively). CD38 was identified as an independent predictor of increased relapse risk, while LAIR expression was associated with a reduced relapse rate.

Conclusion

Expression of CD5, CD19, and CD200 by flow cytometry demonstrated a highly sensitive and accurate diagnostic utility for CLL. Adding both CD31 and CD11c to the predictive model further improved diagnostic specificity, reaching as high as 100%. The identification of relapse‐associated markers provides valuable insights for personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellFlow CytometryBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedAntigens, CDAged, 80 and overAdultImmunophenotypingPrognosisSensitivity and SpecificitySoutheast Asian People

Stichwörter der Autor:innen

CD markersatypical CLLchronic lymphocytic leukemiaflow cytometrylymphoproliferative disorders

Substanzen

Biomarkers, TumorAntigens, CD

Autor:innen und Institutionen

  • Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Internal Medicine, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand.
  • Division of Hematology, Department of Medicine, Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand.
  • Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Hematology, Department of Medicine, Faculty of Medicine, Kon Kaen University, Kon Kaen, Thailand.

ORCID-Profile: Ornnicha Sathitakorn, Kitsada Wudhikarn, Chantana Polprasert

Förderung

  • Ratchadapiseksompotch fund
  • Center of Excellence in Translational Hematology
  • Janssen Pharmaceuticals
  • Janssen Pharmaceutica

Zitieren

APA

Sathitakorn, O., Kobbuaklee, S., Chanswangphuwana, C., Rattanathammethee, T., Makruasi, N., Chintabanyat, A., Chuncharunee, S., Phiphitaporn, P., Khuhapinant, A., Wong, P., Julamanee, J., Thookhamme, C., Norasetthada, L., Bunworasate, U., Wudhikarn, K., Intragumtornchai, T., & Polprasert, C. (2025). Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70116

Vancouver

Sathitakorn O, Kobbuaklee S, Chanswangphuwana C, Rattanathammethee T, Makruasi N, Chintabanyat A, et al. Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group. Journal of Clinical Laboratory Analysis. 2025. doi:10.1002/jcla.70116

BibTeX
@article{Sathitakorn2025,
  author = {Sathitakorn, Ornnicha and Kobbuaklee, Sirorat and Chanswangphuwana, Chantiya and Rattanathammethee, Thanawat and Makruasi, Nisa and Chintabanyat, Anothai and Chuncharunee, Suporn and Phiphitaporn, Pisa and Khuhapinant, Archrob and Wong, Peerapon and Julamanee, Jakrawadee and Thookhamme, Chayapa and Norasetthada, Lalita and Bunworasate, Udomsak and Wudhikarn, Kitsada and Intragumtornchai, Tanin and Polprasert, Chantana},
  title = {Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2025},
  doi = {10.1002/jcla.70116}
}
Kostenlos starten →